Literature DB >> 18936190

Posaconazole mono- or combination therapy for treatment of murine zygomycosis.

Ashraf S Ibrahim1, Teclegiorgis Gebremariam, Julie A Schwartz, John E Edwards, Brad Spellberg.   

Abstract

We compared the efficacy of combination posaconazole-liposomal amphotericin B (LAmB) therapy to monotherapy with either drug in diabetic ketoacidotic or neutropenic mice with disseminated zygomycosis caused by Rhizopus oryzae. Combination therapy was no better than LAmB alone, and posaconazole monotherapy did not improve survival or reduce fungal burden versus placebo.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18936190      PMCID： PMC2630615          DOI： 10.1128/AAC.01124-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Posaconazole as salvage therapy for zygomycosis.

Authors:  R N Greenberg; K Mullane; J-A H van Burik; I Raad; M J Abzug; G Anstead; R Herbrecht; A Langston; K A Marr; G Schiller; M Schuster; J R Wingard; C E Gonzalez; S G Revankar; G Corcoran; R J Kryscio; R Hare
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 2.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases.

Authors:  Maureen M Roden; Theoklis E Zaoutis; Wendy L Buchanan; Tena A Knudsen; Tatyana A Sarkisova; Robert L Schaufele; Michael Sein; Tin Sein; Christine C Chiou; Jaclyn H Chu; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2005-07-29       Impact factor: 9.079

3.  Deferiprone iron chelation as a novel therapy for experimental mucormycosis.

Authors:  Ashraf S Ibrahim; John E Edwards; Yue Fu; Brad Spellberg
Journal:  J Antimicrob Chemother       Date:  2006-08-23       Impact factor: 5.790

4.  Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice.

Authors:  Brad Spellberg; Yue Fu; John E Edwards; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

5.  Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.

Authors:  Ashraf S Ibrahim; Joel C Bowman; Valentina Avanessian; Keturah Brown; Brad Spellberg; John E Edwards; Cameron M Douglas
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

6.  A phagocytic cell line markedly improves survival of infected neutropenic mice.

Authors:  Brad J Spellberg; Mary Collins; Samuel W French; John E Edwards; Yue Fu; Ashraf S Ibrahim
Journal:  J Leukoc Biol       Date:  2005-04-27       Impact factor: 4.962

7.  Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae.

Authors:  Ashraf S Ibrahim; Valentina Avanessian; Brad Spellberg; John E Edwards
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

8.  Activity of posaconazole in treatment of experimental disseminated zygomycosis.

Authors:  Eric Dannaoui; Jacques F G M Meis; David Loebenberg; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

9.  Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.

Authors:  Jo-Anne H van Burik; Roberta S Hare; Howard F Solomon; Michael L Corrado; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2006-02-21       Impact factor: 9.079

10.  In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.

Authors:  Qiu N Sun; Laura K Najvar; Rosie Bocanegra; David Loebenberg; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191
View more
  28 in total

1.  Combination therapy for mucormycosis: why, what, and how?

Authors:  Brad Spellberg; Ashraf Ibrahim; Emmanuel Roilides; Russel E Lewis; Olivier Lortholary; George Petrikkos; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

Review 2.  Mucormycosis, pseudallescheriasis, and other uncommon mold infections.

Authors:  Clifford Quan; Brad Spellberg
Journal:  Proc Am Thorac Soc       Date:  2010-05

3.  Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries.

Authors:  Livio Pagano; Oliver A Cornely; Alessandro Busca; Morena Caira; Simone Cesaro; Cristiana Gasbarrino; Corrado Girmenia; Werner J Heinz; Raoul Herbrecht; Cornelia Lass-Flörl; Annamaria Nosari; Leonardo Potenza; Zdenek Racil; Volker Rickerts; Donald C Sheppard; Arne Simon; Andrew J Ullmann; Caterina Giovanna Valentini; Jörg Janne Vehreschild; Anna Candoni; Maria J G T Vehreschild
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

4.  Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis.

Authors:  Guanpingsheng Luo; Teclegiorgis Gebremariam; Hongkyu Lee; Samuel W French; Nathan P Wiederhold; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

5.  Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy.

Authors:  Jeffrey D Jenks; Sharon L Reed; Danila Seidel; Philipp Koehler; Oliver A Cornely; Sanjay R Mehta; Martin Hoenigl
Journal:  Int J Antimicrob Agents       Date:  2018-08-09       Impact factor: 5.283

Review 6.  Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients.

Authors:  Frederic Lamoth; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

7.  Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.

Authors:  M Mar Rodríguez; F Javier Pastor; Deanna A Sutton; Enrique Calvo; Annette W Fothergill; Valentina Salas; Michael G Rinaldi; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

8.  Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.

Authors:  M Mar Rodríguez; F Javier Pastor; Enrique Calvo; Valentina Salas; Deanna A Sutton; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

9.  Recent advances in the treatment of mucormycosis.

Authors:  Brad Spellberg; Ashraf S Ibrahim
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

10.  Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice.

Authors:  M Mar Rodríguez; Enrique Calvo; Marçal Mariné; F Javier Pastor; Joan Fernandez-Ballart; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.